酪氨酸激酶抑制剂对放射性碘难治性分化型甲状腺癌疗效的Meta分析OA

Objective To investigate the effect of tyrosine kinase inhibitor(TKI)on radioiodine-refractory differentiated thyroid carcinoma(RAI-rDTC).Methods Literature related to RAI-rDTC was retrieved from Wanfang Data,CNKI,VIP,PubMed,Cochrane,EmBase and Medline databases until December 31,2021.Literature quality and experimental bias were referred to the Cochrane quality risk assessment table,and Meta-analysis was performed using RevMan 5.3 software.Results A total of 1384 patients were included in 6 studies.The results of Meta-analysis showed that the median progress free survive(HR=0.30,95%CI:0.18-0.50,P<0.00001)and overall survival(HR=0.70,95%CI:0.57-0.88,P=0.002)in treatment group were significantly longer than those in control group.There was no significant difference in complete response between two groups(RR=3.31,95%CI:0.41-26.89,P=0.26).The partial response in treatment group was significantly higher than that in control group(RR=15.97,95%CI:3.48-73.17,P=0.0004).The incidence of TKI-related adverse reactions above grade 3 in treatment group was significantly higher than that in control group(RR=2.91,95%CI:1.70-4.96,P<0.0001).Conclusion TKI can significantly prolong progress free survive and overall survival in patients with RAI-rDTC,but there are still many adverse reactions.It is necessary to comprehensively evaluate the health status of patients before medication.